Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

~26 mi. (Baton Rouge, Louisiana, +523 more cities)

Ochsner High Grove

Clear Cell Renal Cell Carcinoma

cabozantinib, +2 more drugs

immunotherapy, +1 more type

Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy

~26 mi. (Baton Rouge, Louisiana, +744 more cities)

Ochsner High Grove, +3 more facilities

Breast Carcinoma

axillary lymph node dissection, +1 more drug

radiation therapy, +1 more type

Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)

~26 mi. (Baton Rouge, Louisiana, +147 more cities)

Our Lady of the Lake Regional Medical Center. ( Site 0031)

Cervical Adenocarcinoma, +2 more conditions

brachytherapy, +3 more drugs

chemotherapy, +2 more types

A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease.

~26 mi. (Baton Rouge, Louisiana, +230 more cities)

Research Site

ER Positive, +1 more biomarker

Breast Carcinoma

camizestrant, +3 more drugs

hormone therapy, +1 more type

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

~26 mi. (Baton Rouge, Louisiana, +356 more cities)

Our Lady of the Lake Physician Group, +2 more facilities

HER2 Positive

Invasive Breast Carcinoma

fam-trastuzumab deruxtecan

targeted therapy

Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer

~26 mi. (Baton Rouge, Louisiana, +158 more cities)

Research Site

Adenocarcinoma of the Gastroesophageal Junction, +1 more condition

docetaxel, +4 more drugs

chemotherapy, +1 more type

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

~26 mi. (Baton Rouge, Louisiana, +825 more cities)

Our Lady of the Lake Physicians Group - Medical Oncology, +8 more facilities

AKT1 Mutation, +91 more biomarkers

Breast Carcinoma, +3 more conditions

adavosertib, +26 more drugs

immunotherapy, +1 more type

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

~26 mi. (Baton Rouge, Louisiana, +102 more cities)

Hematology Oncology Clinic

Prostate Carcinoma

abiraterone, +2 more drugs

hormone therapy, +1 more type

Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

~26 mi. (Baton Rouge, Louisiana, +656 more cities)

Ochsner High Grove, +2 more facilities

Deficient DNA Mismatch Repair (dMMR), +8 more biomarkers

Colon Adenocarcinoma, +1 more condition

atezolizumab, +3 more drugs

chemotherapy, +1 more type

Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients

~26 mi. (Baton Rouge, Louisiana, +280 more cities)

MorphoSys Research Site

ALK Fusion, +4 more biomarkers

ALK-Positive Large B-Cell Lymphoma, +7 more conditions

cyclophosphamide, +6 more drugs

chemotherapy, +3 more types

S0820, Adenoma and Second Primary Prevention Trial

~26 mi. (Baton Rouge, Louisiana, +616 more cities)

Ochsner Health Center-Summa, +2 more facilities

Colon Carcinoma, +1 more condition

eflornithine, +2 more drugs

chemotherapy, +1 more type

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

~26 mi. (Baton Rouge, Louisiana, +606 more cities)

Hematology/Oncology Clinic PLLC, +3 more facilities

CD274 Amplification

Angiosarcoma, +26 more conditions

ipilimumab, +1 more drug

immunotherapy